

U.S.S.N. 10/028,547

Filed: December 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

Clean Version of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

Sub P
C1
1. (Twice Amended) A method of treating fibromyalgia syndrome (FMS) comprising administering to an animal subject suffering from FMS, a composition comprising as the active ingredient milnacipran, or a pharmaceutically acceptable salt thereof in an amount effective to treat the chronic pain and fatigue associated with FMS.

Please cancel claims 2-6.

C2
7. The method according to claim 1, wherein the animal subject is human.
3.8. (amended) The method according to claim 1, wherein the amount of milnacipran administered is from about 25 mg to about 400 mg per day.

C3
9. The method according to claim 1, wherein the milnacipran is formulated in a sustained release formulation.

3.1. The method of claim 1 wherein the amount of milnacipran administered is at least 100 mg per day.

4.32. The method of claim 1 wherein the amount of milnacipran administered is between 100 and 400 mg per day.

1.33. The method of claim 1 wherein the amount of milnacipran administered is between 100 and 250 mg per day.

*JP**U*